The Biologics Price Competition and Innovation Act (BPCIA) of 2010 initially posed significant barriers to biosimilar ...

Blue Shield of California will offer an adalimumab biosimilar at a price that is 75% less than the reference product Humira ...

Prime Therapeutics LLC (Prime) today announced new, cost-effective Humira biosimilar solutions, offering clients continued flexibility and choice, along with financial risk mitigation strategies ...

On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which ...

India's bioeconomy has grown rapidly, increasing from $86 billion in 2020 to $137 billion in 2022, with projections to reach ...

A top California health plan is set to offer one of the world's biggest-selling drugs for free in a bid to show the medicine ...

Kiran Mazumdar-Shaw is the executive chairperson of Biocon, a major Indian producer of pharmaceutical ingredients, generics, and biosimilars. Mazumdar-Shaw founded the company in 1978 in the garage of ...

“Biosimilars are clearly a new and big issue for us,” she said, introducing Westminster Health Form’s Biosimilars in the NHS – Commissioning, Development and Engagement with Clinicians and ...

After years of patent protection, biosimilars for Humira are set to enter the US market in 2023. The arrival of these drugs has been widely anticipated throughout the healthcare industry.

Today’s pharmacy innovations provide employees with expanded choices to meet their health care needs. As a result, they ...

Sandoz Canada head office and sales force operations certified carbon neutral by LCL Engineering, Environment & Sustainable ...

(CVS) just announced it was considering a breakup. Why is that important? Spinoffs are one of the best-kept investment ...